Table 2.

Sensitivity analysis of primary and secondary outcomes

Outcome	Sensitivity analyses	Studies (n)	TXA	Placebo	RR or MD	95% CI	P value for effect	P value for heterogeneity
Cerebrovascular accident	Studies randomized not less 100 patients	9	286/2999	318/3011	0.90	0.78–1.05	0.18	0.64
	Study with maximum sample size excluded	21	9/1062	10/1084	0.95	0.43–2.10	0.90	0.86
Reoperation for bleeding	Studies randomized not less 100 patients	8	29/2812	59/2821	0.49	0.32–0.77	< 0.01	0.58
	Study with maximum sample size excluded	15	17/815	30/814	0.59	0.34–1.04	0.07	0.72
Mortality	Studies randomized not less 100 patients	7	31/2870	36/2886	0.87	0.54–1.40	0.56	0.46
	Study with maximum sample size excluded	16	7/875	8/898	0.93	0.38–2.27	0.88	0.75
Myocardial infarction	Studies randomized not less 100 patients	11	286/2999	318/3011	0.90	0.78–1.05	0.18	0.64
	Study with maximum sample size excluded	22	23/1039	25/1045	0.94	0.55–1.61	0.81	0.8
Acute renal insufficiency	Studies randomized not less 100 patients	7	105/2758	102/2769	1.03	0.79–1.35	0.81	0.89
	Study with maximum sample size excluded	13	12/658	14/667	0.88	0.42–1.84	0.73	0.94
Transfusion of any blood products	Studies randomized not less 100 patients	7	954/2494	1400/2504	0.64	0.50–0.81	< 0.01	< 0.01
	Study with maximum sample size excluded	10	139/396	216/363	0.29	0.20–0.40	< 0.01	< 0.01
Postoperative chest tube drainage in the first 24 h	Studies randomized not less 100 patients	7	2824	2850	-208.3	−274.12,-142.48	< 0.01	< 0.01
	Study with maximum sample size excluded	17	802	814	−215.42	−259.48, −171.57	< 0.01	< 0.01

TXA tranexamic acid, (n) the number of cases, RR risk ratio, MD weighted mean difference, CI confidence interval